Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19451442 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo

Indicates status has not been verified in more than two years